文献速递白血病

维生素C和D补充在急性髓系白血病中的应用

Vitamin C and D supplementation in acute myeloid leukemia.
PubMed 文献 · Blood Adv · 2023-01-01

2018年起研究者将维生素C和D加入所有接受强化化疗的急性髓系白血病(AML)患者的支持治疗,比较改变前后患者结局。2015至2020年共纳入431例,262例未补充、169例补充。补充组诱导期细菌或真菌感染、出血或巨噬细胞活化综合征发生率较低,但缓解率、复发率和总生存无差异;NPM1突变患者中补充与更好总生存独立相关(HR 0.52)。

要点

  • 补充维生素C/D未改善整体缓解率、复发率或总生存。
  • 补充组诱导期细菌或真菌感染、出血或巨噬细胞活化综合征发生率较低。
  • NPM1突变患者中补充与更好总生存独立相关(HR 0.52)。

核心结论

  • 维生素C/D补充是安全的,可能影响接受强化化疗的AML患者的结局。

研究设计与样本

  • 自身实践前后对照研究,2015至2020年纳入431例接受强化化疗的AML患者,262例未补充、169例补充维生素C和D。

主要发现

  • 多数患者诊断时维生素C和D水平低。
  • 诱导恢复后补充组维生素D水平较诊断时显著升高,移植前水平显著高于对照组(中位数33 vs 19 ng/mL;P < .0001)。
  • 诱导期补充组细菌或真菌感染、出血或巨噬细胞活化综合征发生率较低,而缓解率、复发率和总生存无差异。
  • 多因素分析显示维生素C/D与NPM1突变存在显著交互作用:NPM1突变患者补充与更好总生存独立相关(HR 0.52;95%CI 0.30-0.90;P = .019),野生型NPM1患者无此关联(HR 1.01;95%CI 0.68-1.51;P = .95)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Recent studies have highlighted the role of vitamin C and D in acute myeloid leukemia (AML). In 2018, we changed our practices to add both vitamins to the supportive care for all consecutive patients with AML undergoing intensive chemotherapy. In this study, we compared the outcomes of patients treated before and after this change in practice. From 2015 to 2020, 431 patients were included, 262 of whom received no supplementation and 169 of whom received vitamin supplementation. Vitamin C and vitamin D was administered from day 10 of chemotherapy until hematologic recovery from induction and consolidation. Most patients presented at diagnosis with low levels of vitamin C and D. Upon recovery from induction, vitamin D levels among the vitamin C/D group significantly increased compared with those at diagnosis, and pretransplant levels were significantly higher in the vitamin C/D group compared with the control group (median of 33 vs 19 ng/mL; P < .0001). During induction, the rates of bacterial or fungal infection, hemorrhage, or macrophage activation syndrome were lower in the vitamin C/D group, whereas there was no difference in response rate, relapse incidence, and overall survival (OS). However, the multivariate analysis for OS showed a significant interaction between vitamin C/D and NPM1 mutation, meaning that vitamin C/D supplementation was significantly and independently associated with better OS in patients with NPM1 mutations (hazard ratio [HR], 0.52; 95% confidence interval [CI], 0.30-0.90; P = .019) compared with patients with wild-type NPM1 (HR, 1.01; 95% CI, 0.68-1.51; P = .95). In conclusion, vitamin C/D supplementation is safe and could influence the outcomes of patients with AML undergoing intensive chemotherapy.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Mouchel PL, Bérard E, Tavitian S, et al. Vitamin C and D supplementation in acute myeloid leukemia. Blood Adv. 2023. PMID: 37671973. doi:10.1182/bloodadvances.2023010559

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。